The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.
G. E. Richardson
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
T. E. Ciuleanu
Honoraria - Amgen
L. Costa
Consultant or Advisory Role - Amgen; Novartis; Roche
Research Funding - Amgen; Novartis
S. J. M. Gans
No relevant relationships to disclose
J. Á. Garcia Saenz
No relevant relationships to disclose
V. Hirsh
Consultant or Advisory Role - Amgen
V. Hungria
No relevant relationships to disclose
M. Krzakowski
No relevant relationships to disclose
C. Manegold
Honoraria - Amgen
H. Nahi
No relevant relationships to disclose
S. Novello
No relevant relationships to disclose
A. L. Petzer
Consultant or Advisory Role - Amgen
M. E. Rader
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
P. Solal-Celigny
Research Funding - Amgen
S. Vadhan-Raj
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
J. F. Vansteenkiste
Research Funding - Amgen
P. J. Woll
Consultant or Advisory Role - Amgen
C. Ke
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
K. Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Yeh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen